

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



JL

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 9/26	A1	(11) International Publication Number: WO 90/03165 (43) International Publication Date: 5 April 1990 (05.04.90)
(21) International Application Number: PCT/US89/03968 (22) International Filing Date: 14 September 1989 (14.09.89) (30) Priority data: 246,368 19 September 1988 (19.09.88) US (71) Applicant: EDWARD MENDELL CO., INC. [US/US]; 501 Route 52, Carmel, NY 10512 (US). (72) Inventors: BAICHWAL, Anand, R. ; 3801 Cherry Hill Drive, Poughkeepsie, NY 12603 (US). STANIFORTH, John, N. ; 170 Bloomfield Road High Trees, Bath BA2 2AT (GB). (74) Agents: MADSEN, Kenneth, E. et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).		(81) Designated States: AU, DK, FI, JP, KR, NO. Published <i>With international search report.</i>
(54) Title: DIRECTLY COMPRESSIBLE SUSTAINED RELEASE EXCIPIENT (57) Abstract A free-flowing directly compressible granulation useful as a slow release pharmaceutical excipient is disclosed. The excipient includes a hydrophilic matrix which includes a heteropolysaccharide and a polysaccharide material capable of cross-linking the heteropolysaccharide, and an inert diluent.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

-1-

DIRECTLY COMPRESSIBLE
SUSTAINED RELEASE EXCIPIENT

FIELD OF THE INVENTION

The present invention relates to a free flowing, directly compressible granulation forming a sustained release pharmaceutical excipient product which can be blended with a wide range of therapeutically active medicaments and tableted.

BACKGROUND OF THE INVENTION

Many attempts have been made in the pharmaceutical art to provide a method by which therapeutically active medicaments can be directly tableted or mixed with a direct compression vehicle and thereafter directly tableted.

Very few therapeutically active medicaments can be directly tableted due to unacceptable flow characteristics and compressibility factors of the crystalline or powdered medicament, and also due to the small amounts of medicament needed to provide the desired effect. Therefore, it is a common practice to

-2-

use an inert ingredient, i.e., excipients, diluents, fillers, binders and the like, such that the combination of the same with the medicament provides a material which can be directly compressed into tablets. In order
5 to provide a directly compressible product, these excipients must have certain physical properties, including flowability, sufficient particle size distribution, binding ability, acceptable bulk and tap densities, and acceptable dissolution properties in
10 order to release the medicament upon oral administration.

U.S. Patent No. 3,639,169 (Broeg et al.) discloses one such direct compression vehicle for a therapeutically active medicament which consists of an
15 insoluble or soluble diluent such as lactose dispersed in a matrix of a hydrophilic hydratable high polymer such as hydrophilic polysaccharides, hydrocolloids or proteinaceous materials. The polymer, diluent and water are mixed and the resulting dispersion is dried, forming
20 a film. The cooled film is fragmented, ground to the desired particle size and then blended with a desired medicament.

In another method disclosed in U.S. 3,079,303 (Raff et al.), a granular excipient for making tablets is
25 prepared by spray drying a slurry of 50-98% filler, 1-50% disintegrant, and 1-50% binder. A medicament is then added to the excipient and the finished product is tableted.

It has become desirable to provide pharmaceutical
30 formulations which utilize slow release profiles, an

-3-

objective not contemplated in Broeg et al., Raff et al. or other similar prior art. The advantages of slow release products are well known in the pharmaceutical field and include the ability to maintain a desired
5 blood level over a longer period of time while increasing patient compliance by reducing the number of administrations necessary to achieve the same.

Slow release excipients have been developed which attain their goals by a wide variety of methods. For
10 instance, U.S. Patent No. 3,629,393 (Nakamoto) utilizes a three-component system to provide slow release tablets in which granules of an active ingredient with a hydrophobic salt of a fatty acid and a polymer are combined with granules of a hydrocolloid and a carrier
15 and granules of a carrier and an active or a buffering agent and then directly compressed into tablets. U.S. Patent No. 3,728,445 (Bardani) discloses slow release tablets formed by mixing an active ingredient with a solid sugar excipient, granulating the same by
20 moistening with a cellulose acetate phthalate solution, evaporating the solvent, recovering the granules and compressing under high pressure. These disclosures concentrate their attention to the type and combination of polymers and/or gums used, and processes for mixing
25 the same, and therefore have not provided a directly compressible form of gums/polymers and adjuvants which can be used for a wide range of medicaments.

Other slow release excipients are disclosed in the prior art which are directed to particular
30 therapeutically active medicaments.

-4-

In one such disclosure, U.S. Patent No, 3,456,049 (Hotko et al.), a slow release benzothiadiazine diuretic tablets are prepared by mixing a fatty substance such as hydrogenated vegetable oil, alginic acid, a granulating liquid, a potassium salt and the benzothiadiazine. The wet mass is screened, dried, and then compressed into tablets. Similarly, U.S. Patent No. 4,692,337 (Ukigaya et al.) provides a slow release excipient for theophylline which utilizes 5-200 parts of ethyl cellulose for each 100 parts theophylline, and optionally contains a filler such as lactose or a lubricant. The ingredients are mixed and compression molded into tablets. In yet another example, U.S. Patent No. 4,308,251 (Dunn et al.), a sustained release aspirin formulation in which 0.8-1.6 percent of a release controlling agent (cellulose acetate phthalate) and 1.0-7.5 percent of an erosion-promoting agent (corn starch) by weight per tablet. A wet granular mass is formed, dried, reduced in particle size and compressed into tablets.

-5-

More recently, a great deal of attention in the pharmaceutical field has turned to the use of various hydrocolloid materials such as hydroxypropylmethyl cellulose in providing a slow release matrix for a variety of medicaments.

For example, U.S. Patent No. 4,389,393 (Schor et al.) describes a slow release carrier base material of one or more hydroxypropylmethyl celluloses and up to 30% by weight of a mixture of methylcellulose, sodium carboxymethylcellulose and/or cellulose either which can be mixed with a medicament and other needed ingredients such as binders, lubricants, etc. and then tableted. At least one of the hydroxypropylmethyl celluloses must have a methoxy content of 16-24% by weight, a hydroxypropyl content of 4-32% by weight, and a number average molecular weight of at least 50,000. The carrier base constitutes less than about one third of the weight of the solid unit dosage form.

It is acknowledged in Schor et al. that in order to make tablets using this carrier base, other ingredients which are conventional in tablet making must necessarily be included, such as binders, fillers, disintegrating agents and the like. Only the completed mixture, which includes these additional ingredients, possess sufficient properties to produce tablets having the necessary hardness and low level of friability. Thus, the carrier base of the Schor et al. disclosure is not directed to the tableting aspects.

U.S. Patent No. 4,704,285 (Alderman) discloses solid slow release tablets containing 5-90%

-6-

hydroxypropyl cellulose ether, 5-75% of an optional additional hydrophilic colloid such as hydroxypropylmethyl cellulose, an effective amount of an active medicament, and optional binders, lubricants, 5 glidants, fillers, etc. The hydroxypropyl cellulose ether is in the form of a finely sized powder and provides a longer release pattern than identical compositions having coarser particles. However, Alderman acknowledges the necessity of the additional 10 excipients in order to form an acceptable solid tablet, (i.e. fillers, binders, lubricants and glidants). In preferred embodiments, these excipients comprise from 63.5-94% of the tablet.

The carrier bases which provide the slow release 15 profiles in these disclosures can only be compressed into a tablet or a solid dosage form with the aid of other conventional tableting adjuvants such as binders and the like, and therefore contribute only to the slow release aspect of the final solid unit dosage form and 20 not to the tableting aspects. In other words, in each of these disclosures it is necessary for to first determine the physical properties of the active medicament to be tableted and thereafter proceed through a series of trial and error experiments in order to 25 determine the optimal amount of gums/polymers and other adjuvants to produce the right formulation which is free flowing and which can be compressed to a slow release solid dosage unit. This procedure is time intensive and costly.

30 Similarly, slow release excipients disclosed to

-7-

date which incorporate virtually any synthetic polymer such as hydroxypropylmethylcellulose, methyl cellulose, polyvinylpyrrolidone, and any natural gum such as accacia, tragacanth, alginates, chitosan, xanthan, 5 pectin and others to date have been mainly directed to the slow release aspect and do not satisfactorily address the tableting aspect. This is because these materials are not available in the necessary physical form that is essential for forming a solid unit dosage 10 form.

The failure of slow release excipients such of the above to be regarded as to their tableting properties is due, for instance, to their necessarily very fine particle size, which property does not lend itself well 15 to flowability. Also, hydroxypropylmethyl cellulose polymers and the like are not particularly good binding agents, a problem which is amplified when other poorly binding excipients or medicaments are included in a formulation. Thus, at higher percentages of such 20 polymers in the final mixture, it becomes difficult if not impossible to provide a good flowing tablet formulation for direct compression without the use of further excipients, and experimentation.

The tableting aspect has been addressed, albeit 25 unsatisfactorily, in U.S. Patent No. 4,590,062 (Jang). Jang discloses a dry direct compressed slow release tablet containing from 0.01 to 95 parts by weight of an active ingredient combined with a matrix blend of 1-96 parts of a hydrophobic carbohydrate polymer and 4-99 30 parts of a wax, and a fatty acid material or neutral

-8-

lipid. The tablets can be made by dry blending the active ingredient with the matrix blend and compressing. However, while this combination of ingredients can provide a directly compressible tablet, the formulator
5 is still required to perform a great deal of experimentation to provide the correct release profile for the chose medicament, given the wide range of wax (used for its binding and compacting properties) which can be included.

10 It is therefore an object of the present invention to provide a free-flowing directly compressible slow release excipient which can be used for a wide variety of therapeutically active medicaments.

It is another object of the present invention to
15 provide an excipient having the properties set forth above which can be used with both relatively soluble and relatively insoluble therapeutically active medicaments.

It is a further object of the present invention to provide a free-flowing directly compressible slow
20 release excipient which is relatively inexpensive to manufacture due to the lack of coatings and expensive equipment.

SUMMARY OF THE INVENTION

In accordance with the above-mentioned objectives,
25 the present invention provides a directly compressible, free-flowing slow release granulation for use as a pharmaceutical excipient comprising from about 20 to about 70 percent or more by weight of a hydrophilic material comprising a heteropolysaccharide and a
30 polysaccharide material capable of cross-linking the

-9-

heteropolysaccharide in the presence of aqueous solutions, and from about 30 to about 80 percent by weight of an inert pharmaceutical filler. This excipient can be mixed with a wide range of
5 therapeutically active medicaments and then directly compressed into solid dosage forms such as tablets. The tablets thus formed slowly release the medicament when ingested and exposed to gastric fluids. By varying the amount of excipient relative to the medicament, a slow
10 release profile can be attained.

The heteropolysaccharide comprises from about 20 to about 80 percent and the polysaccharide material comprises from about 80 to about 20 percent by weight of the hydrophilic matrix. Preferably, the ratio of
15 heteropolysaccharide to polysaccharide material is about 1:1.

In preferred embodiments, the heteropolysaccharide comprises xanthan gum or a derivative thereof.

In another preferred embodiment, the polysaccharide
20 material comprises one or more galactomannans. Most preferably, the polysaccharide material comprises locust bean gum.

In yet another preferred embodiment, the inert pharmaceutical filler comprises lactose, dextrose,
25 sucrose, sorbitol, xylitol, fructose or mixtures thereof.

The present invention also provides a slow release granulation for use as a directly compressible pharmaceutical excipient, comprising a
30 heteropolysaccharide or a gum having similar properties

-10-

and a polysaccharide material capable of cross-linking the heteropolysaccharide in the presence of water, the ratio of the heteropolysaccharide to the polysaccharide material being from about 1:1 to about 4:1.

5 The present invention also provides a slow release tablet for oral administration comprising (I) a hydrophillic material comprising (a) a heteropolysaccharide; or (b) a heteropolysaccharide and a cross-linking agent capable of cross-linking said
10 heteropolysaccharide; or (c) a mixture of (a), (b) and a polysaccharide gum; and (II) an inert pharmaceutical filler comprising up to about 80 percent by weight of the tablet; and (III) an effective amount of a therapeutically active ingredient.

15 In addition, the present invention provides a method for providing a universal tableting excipient for controlled release of therapeutically active medicaments having varied solubilities in water, comprising
20 determining the solubility of a therapeutically active medicament which is to be tableted; 30 to about 50 percent by weight of a hydrophilic material comprising a heteropolysaccharide and a polysaccharide capable of cross-linking said heteropolysaccharide in the presence of aqueous solutions, and up to 80 percent by weight of
25 an inert pharmaceutical filler; providing a final mixed product having a ratio of said therapeutically active medicament to said hydrophilic material of about 1:3-7 depending upon the relative solubility of the medicament, amount of medicament needed (dose), the
30 desired total weight of the tablet, the compression

-11-

force used, etc.; and thereafter directly compressing the resulting blend to form a tablet. Generally, the more soluble the medicament, the greater the amount of hydrophilic material needed to produce a slow release of the medicament.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

FIGURE 1 is a graphical representation of the dissolution curves provided by Examples 3-6;

FIGURE 2 is a graphical representation of the dissolution curves provided by Examples 16-19;

FIGURE 3 is a graphical representation of the dissolution curves provided by Examples 18, 20 and 28;

FIGURE 4 is a graphical representation of the dissolution curve provided by Example 18 as compared to Comparative Example C;

FIGURE 5 is a graphical representation of the dissolution curve provided by Examples 29-31 (in different pH's); and

FIGURE 6 is a graphical representation of the viscosities of Examples 32-36.

DETAILED DESCRIPTION

The excipients of the present invention have been preoptimized by providing an excipient product which may be mixed with a wide range of medicaments and directly compressed into solid dosage forms, without the aid of

-12-

the usual pharmaceutical dry or wet binders, fillers, disintegrants, glidants etc. which must be added in prior art compositions to obtain an acceptable solid dosage form. Thus, the excipients of the present invention substantially overcome the need for conducting further experimentation needed to optimize release characteristics and tableting properties for a particular therapeutically active medicament.

In other words, the present invention provides a novel slow release excipient product which contains a combination of ingredients in preselected proportions to each other which provides a desired slow release profile for a wide variety of drugs. Thus, once the excipient product is admixed with an active medicament (and optional lubricant) in a ratio to the hydrophilic matrix in accordance with the present invention, the resulting mixture may be directly compressed into solid dosage forms.

Xanthan gum, the preferred heteropolysaccharide, is produced by microorganisms, for instance, by fermentation with the organism *xanthomonas compestris*. Most preferred is xanthan gum which is a high molecular weight (10^6) heteropolysaccharide. Xanthan gum contains D-glucose, D-mannose, D-glucuronate in the molar ratio of 2.8:2.0:2.0, and is partially acetylated with about 4.7% acetyl. Xanthan gum also includes about 3% pyruvate, which is attached to a single unit D-glucopyromosyl side chain as a ketal. It dissolves in hot or cold water and the viscosity of aqueous solutions of xanthan gum is only slightly affected by changes in

-13-

the pH of a solution between 1 and 11.

Other preferred heteropolysaccharides include derivatives of xanthan gum, such as deacylated xanthan gum, the carboxymethyl ether, and the propylene glycol ester.

The polysaccharide materials used in the present invention which are capable of cross-linking with the heteropolysaccharide include the galactomannans, i.e., polysaccharides which are composed solely of mannose and galactose. A possible mechanism for the interaction between the galactomannan and the heteropolysaccharide involves the interaction between the helical regions of the heteropolysaccharide and the unsubstituted mannose regions of the galactomannan. Galactomannans which have higher proportions of unsubstituted mannose regions have been found to achieve more interaction with the heteropolysaccharide. Hence, locust bean gum, which has a higher ratio of mannose to galactose, is especially preferred as compared to other galactomannans such as guar and hydroxypropyl guar.

Other polysaccharide gums may also be added to the hydrophilic material in addition to the above-mentioned ingredients. These additional ingredients comprise other polysaccharide gums which may or may not cross-link with the heteropolysaccharides such as the alginates, tragacanth, accacia, karaya, agar, pectins, carrageenan, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, mixtures thereof, and the like.

Two steps which are generally required for gelation

-14-

are the fast hydration of the macromolecules which comprise the hydrophilic material and thereafter the association of the molecules to form gels. Thus, two important properties of a hydrophilic gel matrix which are needed for application in a slow release system are the fast hydration of the system and a matrix having a high gel strength. These two important properties which are necessary to achieve a slow release hydrophilic matrix are maximized in the present invention by the particular combination of materials. In particular, heteropolysaccharides such as xanthan gum have excellent water wicking properties which provide fast hydration. On the other hand, the combination of xanthan gum with polysaccharides materials and the like which are capable of cross-linking the rigid helical ordered structure of the xanthan gum (i.e. with unsubstituted mannose regions in galactomannans) thereby act synergistically to provide a higher than expected viscosity (i.e., high gel strength) of the matrix.

Certain other polysaccharide gums, including alginic acid derivatives, hydrocolloids, etc. also are believed to act synergistically with xanthan gum to produce matrices having high gel strength. The combination of xanthan gum with locust bean gum with or without the other polysaccharide gums is especially preferred. However, the combination of any polysaccharide gums known to produce a synergistic effect when exposed to aqueous solutions may be used in accordance with the present invention. By synergistic effect it is meant that the combination of two or more

-15-

polysaccharide gums produce a higher viscosity and/or faster hydration than that which would be expected by either of the gums alone. One example of a combination of polysaccharide gums which has been reported to exhibit such synergism in food products is kappa carrageenan and a galactomannan such as guar gum and/or locust bean gum. Additionally, the combination of propylene glycol alginate and sodium carboxymethylcellulose has also been reported to exhibit a synergistic effect as a stabilizer in fruit juices in U.S. Patent No. 4,433,000. This list is not meant to be exclusive, and many other synergistic combinations will be readily apparent to those skilled in the art.

Mixtures of xanthan gum and locust bean gum in a ratio from about 20:1 to about 1:10 are disclosed in U.S. Patent No. 3,726,690 (Schuppner) as being useful to minimize serum separation in amounts of 0.2 - 0.6% by weight of acidified food products. In addition, mixtures of xanthan gum/locust bean gum are commercially available as Lygomme H96 from Satia and are recommended for uses such as syrup thickening, suspension of active components and emulsion stabilization. However, there has been no recognition in the art that granulations of xanthan gum, locust bean gum and an inert diluent can be mixed with an active medicament and thereafter directly compressed to form slow release tablets.

In the present invention it has been discovered that the slow release properties of the tablets are optimized when the ratio of xanthan gum to polysaccharide material (i.e., locust bean gum, etc.) is

-16-

about 1:1, although xanthan gum in an amount of from about 20 to about 80 percent or more by weight of the hydrophilic material provides an acceptable slow release product.

5 Upon oral ingestion and contact with gastric fluid, the slow release tablets prepared according to the present invention swell and gel to form a hydrophilic gel matrix from which the drug is released. The swelling of the matrix causes a reduction in the bulk
10 density of the tablet and provides the buoyancy necessary to allow the gel mass to float on the stomach contents to provide a slow delivery of the medicament. The matrix, the size of which is dependent upon the size of the original tablet, can swell considerably and
15 become obstructed near the opening to the pylorus. Since the medicament is dispersed throughout the tablet (and consequently throughout the gel matrix), a constant amount of drug can be released per unit time in vivo by dispersion or erosion of the outer portions of the
20 matrix. This phenomenon is commonly referred to as a zero order release profile or zero order kinetics. The process continues, with the matrix remaining buoyant in the stomach, until substantially all of the medicament is released. The chemistry of certain of the
25 ingredients comprising the excipients of the present invention such as xanthan gum is such that the excipients are considered to be self-buffering agents which are substantially insensitive to the solubility of the medicament and likewise insensitive to the pH
30 changes along the length of the gastrointestinal tract.

-17-

Moreover, the chemistry of the ingredients comprising the excipients of the present invention is believed to be similar to certain known muco adhesive substances such as polycarbophil. Muco adhesive properties are
5 desirable for buccal delivery systems. Thus, it may be possible that the gel system could potentially loosely interact with the mucin in the gastrointestinal tract and thereby provide another mode by which a constant rate of delivery of the medicament is achieved. The
10 above hypothesis is included for discussion purposes only and is not intended to limit the scope of the present invention.

These two phenomenons, i.e., buoyancy of the gel matrix and the mucoadhesive properties discussed above,
15 are possible mechanisms by which the gel matrix of the present invention could interact with the mucin and fluids of the gastrointestinal tract and provide a constant rate of delivery of the medicament. Other mechanisms are possible and therefore this hypothesis is
20 not meant to limit the scope of the present invention.

Any generally accepted soluble or insoluble inert pharmaceutical filler (diluent) material can be used, including sucrose, dextrose, lactose, microcrystalline cellulose, xylitol, fructose, sorbitol, mixtures thereof
25 and the like. However, it is preferred that a soluble pharmaceutical filler such as lactose, dextrose, sucrose, or mixtures thereof be used.

An effective amount of any generally accepted pharmaceutical lubricant, including the calcium or
30 magnesium soaps may be added to the above-mentioned

-18-

ingredients of the excipient be added at the time the medicament is added, or in any event prior to compression into a solid dosage form. Most preferred is magnesium stearate in an amount of about 0.5-3% by weight of the solid dosage form.

The combination of the hydrophilic material (i.e., a mixture of xanthan gum and locust bean gum) with the inert diluent provides a ready to use product in which a formulator need only blend the desired active medicament and an optional lubricant with the excipient and then compress the mixture to form slow release tablets. The excipient may comprise a physical admix of the gums along with a soluble excipient such as compressible sucrose, lactose or dextrose, although it is preferred to granulate or agglomerate the gums with plain (i.e., crystalline) sucrose, lactose, dextrose, etc. to form an excipient. The granulate form has certain advantages including the fact that it can be optimized for flow and compressibility; it can be tableted, formulated in a capsule, extruded and spheronized with an active medicament to form pellets, etc.

The pharmaceutical excipients prepared in accordance with the present invention are preferably subjected to wet granulation before the medicament is added, although the ingredients of the present excipient can be held together by any agglomeration technique to yield an acceptable excipient product. In this technique, the desired amounts of the heteropolysaccharide, the polysaccharide material, and the inert filler are mixed together and thereafter a

-19-

moistening agent such as water, propylene glycol, glycerol, alcohol or the like is added to prepare a moistened mass. Next, the moistened mass is dried. The dried mass is then milled with conventional equipment
5 into granules.

Thereafter, the excipient product is ready to use. The excipient is mixed in the desired proportion with a therapeutically active medicament and optional lubricant. The complete mixture, in an amount
10 sufficient to make a uniform batch of tablets, is then subjected to tableting in a conventional production scale tableting machine at normal compression pressures, i.e. about 2000-16000 lbs/sq. in. However, the mixture should not be compressed to such a degree that there is
15 subsequent difficulty in its hydration when exposed to gastric fluid.

The average particle size of the granulated excipient of the present invention ranges from about 50 microns to about 400 microns and preferably from about
20 185 microns to about 265 microns. The particle size of the granulation is not narrowly critical, the important parameter being that the average particle size of the granules, must permit the formation of a directly compressible excipient which forms pharmaceutically
25 acceptable tablets. The desired tap and bulk densities of the granulation of the present invention are normally between from about 0.3 to about 0.8 g/ml, with an average density of from about 0.5 to about 0.7 g/ml. For best results, the tablets formed from the
30 granulations of the present invention are from about 6

-20-

to about 8 kg hardness. The average flow of the granulations prepared in accordance with the present invention are from about 25 to about 40 g/sec.

The ratio of medicament to the hydrophilic material is based in part upon the relatively solubility of the medicament and the desired rate of release. For instance, the ratio of medicament to hydrophilic material can be adjusted to yield a product wherein 50 percent of the medicament will dissolve in distilled water within about 3.5-5 hours if a 6-8 hour dosing preparation is desired. This is accomplished by providing a ratio of medicament to hydrophilic material of about 1:3-7 for a wide range of medicaments of varying solubilities. However, it would be obvious to one skilled in the art that by varying this proportion and/or the total weight of the tablet, etc., one can achieve different slow release profiles, and may extend the dissolution of some medicaments to about 24 hours. If the medicament is relatively insoluble, the ratio of medicament to hydrophilic material tends to be smaller, while if the medicament is relatively soluble, the ratio tends to be toward the greater end. By "relatively insoluble", it is meant that the medicament exhibits a solubility which is defined in the United States Pharmacopeia (USP) XXI, page 7 as requiring about 10-30 parts solvent for 1 part solute (described therein as "soluble"). An example of a medicament which is considered relatively insoluble for the purposes of the present invention is propranol hydrochloride, which has a solubility of about 1 gram in 20ml of water or

-21-

alcohol. By "relatively soluble", it is meant that the medicament exhibits a solubility which is defined in the USP XXI, page 7 as requiring from about 1-10 parts solvent per 1 part solute (described therein as "freely soluble"). An example of a medicament which is considered relatively soluble for the purposes of the present invention is chlorpheniramine maleate, which has a solubility of 1g in 4ml of water or 10ml of alcohol. These examples have been chosen because they represent the "extremes" in solubilities of many of the medicaments contemplated for use in the present invention. Examples of other medicaments which have solubilities falling within these approximate parameters may be determined from any number of sources such as the Solubility Reference Table found in the USP XXI, pages 1484-9.

The excipient product of the present invention is also contemplated for use in conjunction with insoluble medicaments. By "insoluble", it is meant that the medicament exhibits a solubility which is defined in the USP XXI, page 7 as requiring from about 30-1000 parts solvent per 1 part solute (described) therein as "sparingly soluble" and "slightly soluble"). In such circumstances, the excipient product will be acting to control the release of the medicament rather than necessarily slowing its release. An example of such an insoluble medicament is theophylline.

As previously mentioned, the excipient product of the present invention can be used in conjunction with a wide range of medicaments. Since precise dosing is not

-22-

very critical in medicaments having a wide therapeutic window, the present invention is especially well-suited for the same. The therapeutic window is commonly defined as the difference between the minimum effective
5 blood concentration and the maximum effective blood concentration and the toxic concentration of the medicament.

Examples of such medicaments which can be used in accordance with the present invention include
10 analgesics, antihistamines decongestants, laxatives, antacids, vitamins, anti-infectives, anti-inflammatory, antibiotics, vasocenstrictors, vasodilators, psychotropics, stimulants including appetite suppressants, diuretics, anti-asthmatics,
15 diuretics, anti-spasmodics, antidiarrheals, expectorants, mucolytics, cough suppressants, hypnotics, psychotropics, sedatives and others.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The following examples illustrate various aspects
20 of the present invention. They are not to be construed to limit the claims in any manner whatsoever.

-23-

Example 1

A slow release excipient according to the present invention is prepared as follows. First, 600g of sucrose and 300g of a mixture of xanthan gum and locust bean gum in approximately a 1:1 ratio, all in powder form having an average particle size of less than about 50 microns, are blended for two minutes in a granulator (i.e., a high speed mixer having a combination chopper/impeller). About 125 ml of water is added to the mixture until there is a sharp rise in the power consumed (about 2-3 minutes). The mixed product, which is now in the form of granules, is removed from the granulator and dried in a convection air-oven for 24 hours at a temperature of about 40-60°C. The dried granulation is then passed through a 20 mesh screen. The product is now ready to be used as a slow release excipient which is suitable for direct compression with any active medicament to form a slow release tablet.

20

Example 2

Slow release tablets according to the present invention are prepared as follows. The excipient of Example 1 is first blended with chlorpheniramine maleate for 10 minutes in a V-blender. Magnesium stearate is then added as a lubricant and the mixture is blended for an additional 5 minutes. The final composition of the mixture is about 87.5% of the excipient of Example 1, 12% chlorpheniramine maleate, and 0.5% magnesium stearate by weight.

30

-24-

The mixture is then compressed on a Stokes RB-2 rotary tablet press with sixteen stations, the target weight of the tablets being 100 mg and the crushing strength about 6-8 kgs.

5

Example 3-15

Slow release chlorpheniramine maleate tablets are prepared according to the procedures set forth in Examples 1 and 2, except that the excipient formulation is varied such that the amount of hydrophilic material (for purposes of the present examples referred to as "gums") relative to the total amount of excipient is varied from 20 - 50%. In each of Examples 3-15, the gums are xanthan gum/locust bean gum in approximately a 1:1 ratio. In Examples 3-8, the inert diluent is dextrose. In Examples 9-11, the inert diluent is sucrose. The inert diluent in Examples 12 and 13 is lactose, while in Examples 14 and 15 the inert diluent is a 50/50 mixture of lactose and dextrose. In each of Examples 3-15, the total weight of the tablets is 100mg. The amount of chlorpheniramine maleate in each of these Examples is 12mg except for Example 8, in which only 8mg of the drug were incorporated.

In addition, comparative examples A and B are prepared. Example A is provided with an excipient comprising 30% hydroxypropylmethyl cellulose (grade K15M, available from Dow Chemical) and 70% dextrose. Example B as provided with an excipient comprising 30% hydroxypropylmethyl cellulose (grade K4M, available from Dow Chemical) and 70% dextrose. Comparative Examples A and B include 12mg chlorpheniramine maleate in 100 mg

-25-

tablets.

The granules are tested for tap and bulk density. In addition, the average particle size of the granulations is determined. The results are set forth in Table 1. Thereafter, the tablets produced in Examples 3-15 and comparative examples A and B are tested for dissolution in distilled water in an automated USP dissolution apparatus. The data is represented as the percentage of chlorpheniramine maleate released versus time. The results are provided in Table 2.

As can be seen from the dissolution data provided in Table 2, Examples 4-6, 11, 13 and 15 provide dissolution profiles whereby 50% of the drug dissolves in from about 3.5 - 5.5 hours. Examples 3, 8, 9, 10 and 14, on the other hand, produced dissolution profiles in which 50% of the drug dissolved within 3 hours. The difference in dissolution rates is related to the ratio of drug to the gums (in addition to other criteria, such as the total amount of gums in the tablet, etc.). In particular, dissolution of 50% of the drug in 3.5 - 5.5 hours is accomplished with drug/gums ratios of 1:2.2 - 3.8, while the shorter dissolution times are accomplished with a drug/gums ratios of 1:1.5 - 2.2. The slight overlap is due to the choice of inert diluents. Comparative Examples A and B (which included only a hydrocolloid as the gum and which did not include the heteropolysaccharide and cross-linking agent of the present invention) only provide a T_{50} of 1-1.5 hours when utilizing comparable amounts of gum.

-26-

Figure 1 is a graphical representation of the dissolution curves of Examples 3-6. As can be seen from the graph, the dissolution curves of Examples 4-6 in which the hydrophilic material (i.e., the gums) comprise from 30-50% of the tablet, are similar, while Example 2 (20% gum) shows a much faster dissolution rate. The dissolution curves obtained when other diluents are used and the percentage of gums in the tablet changed also reflected this result.

-27-

TABLE 1Chlorpheniramine Maleate Tablets (100mg)

5

10	<u>Example</u>	<u>Diluent</u>	<u>Amt Drug</u>	<u>% Gums in Excipient</u>	<u>Ratio of Drug/Gums</u>	<u>Average Particle size (microns)</u>	<u>D_B²</u>	<u>D_T³</u>
	3	Dextrose	12mg	20%	1:1.5	239	0.61	0.72
	4	Dextrose	12mg	30%	1:2.2	217	0.64	0.76
15	5	Dextrose	12mg	40%	1:3	187	0.64	0.78
	6	Dextrose	12mg	50%	1:3.6	202	0.57	0.70
	7	Dextrose	12mg	33%	1:2.4	206	0.60	0.72
	8	Dextrose	8mg	33%	1:3.8	206	0.60	0.72
	9	Sucrose	12mg	20%	1:1.5	265	0.59	0.70
20	10	Sucrose	12mg	30%	1:2.2	252	0.58	0.71
	11	Sucrose	12mg	40%	1:3	209	0.59	0.75
	12	Lactose	12mg	30%	1:2.2	178	0.65	0.81
	13	Lactose	12mg	40%	1:3	185	0.62	0.76
	14	L/D ¹	12mg	30%	1:2.2	227	0.57	0.69
25	15	L/D ¹	12mg	40%	1:3	221	0.59	0.70
	A	Dextrose	12mg	30%	1:2.2	226	0.43	0.56
	B	Dextrose	12mg	30%	1:2.2	233	0.46	0.58

30 1 denotes a 50/50 mixture of lactose and dextrose

2 denotes bulk density

3 denotes tap density

-28-

TABLE 2

Chlorpheniramine Maleate Tablets (100mg)

5

Dissolution Data (Distilled Water)

	<u>Example</u>	<u>2hr</u>	<u>4hr</u>	<u>8hr</u>	<u>T</u> ₅₀ ⁴	<u>T</u> ₉₀ ⁵
10						
	3	63.63	85.69	100	1-1.5	3.5-4
	4	34.37	51.69	82.61	3.5-4	9-9.5
	5	27.05	43.05	72.74	4.5-5	10.5-11
15	6	26.68	40.85	69.16	5-5.5	10.5-11
	7	35.31	52.84	75.43	3-4	10-11
	8	39.29	61.64	92.21	2-3	7-8
	9	55.87	76.61	96.96	1.5-2	6-6.5
	10	40.15	59.32	84.59	2.5-3	8.5-9
20	11	26.18	42.52	68.10	4-4.5	11-11.5
	12	41.08	54.56	79.03	3-3.5	9-9.5
	13	30.68	45.74	73.26	4.5-5	10-10.5
	14	43.77	68.11	100	2-2.5	6-6.5
	15	27.17	42.10	70.34	5.5	10.5-11
25	A	59.55	82.44	95.44	1-1.5	5.5-6
	B	69.44	95.22	100	1-1.5	2.5-3

4 denotes the time needed for 50% of the medicament to be released.

30

5 denotes the time needed for 90% of the medicament to be released.

Examples 16-19

Slow release propranolol hydrochloride tablets are
 35 prepared according to the procedures set forth in
 Examples 1 and 2, except that the excipient formulation
 is varied such that the amount of hydrophilic material
 (referred to as "gums") relative to the total amount of

excipient is varied between 40 and 50% and the total weight of the tablets varied from 200-350mg. In each of Examples 16-19, the gums are xanthan gum/locust bean gum in approximately a 1:1 ratio and the amount of propranol
5 hydrochloride is 20mg. In Example 16, the inert diluent is lactose. In Example 17, the inert diluent is a 50/50 mixture of lactose and dextrose. Finally, in Examples 18 and 19, the inert diluent is dextrose and sucrose, respectively.

10 The granulations which are produced are tested for tap and bulk density. In addition, the average particle size of the granulations are determined. The results are set forth in Table 3. Thereafter, the tablets produced are tested for dissolution in distilled water
15 in a USP dissolution apparatus which is automated. The data is represented as the percentage of propranol hydrochloride released versus time. The results are provided in Table 4.

As can be seen by the dissolution data provided in
20 Table 4, each of Examples 16-19 provided a dissolution profile in which 50% of the drug is released in 8.5 to 10 hours. Once again, the dissolution rates are related

-30-

to the ratio of drug to gums, with slight variances due to the choice of inert diluent. The importance of the total weight of the tablet in affecting the drug/gums ratio is also shown.

5

TABLE 3Propranolol Hydrochloride Tablets

10

15	<u>Example</u>	<u>Diluent</u>	<u>% Gums in Excipient</u>	<u>Total Weight of Tablet</u>	<u>Average Particle size (microns)</u>	<u>Ratio of Drug/Gums</u>
	16	Lactose	40%	350mg	185	1:6.6
	17	L/D	40%	350mg	221	1:6.6
20	18	Dextrose	50%	225mg	202	1:5
	19	Sucrose	40%	200mg	209	1:3.6

-31-

TABLE 4

Propranolol Hydrochloride Tablets

5

Dissolution Data (Distilled Water)

10	<u>Example</u>	<u>2hr</u>	<u>4hr</u>	<u>8hr</u>	<u>T₅₀</u>	<u>T₉₀</u>
	16	11.35	19.55	37.55	10	15-15.5
	17	13.40	22.05	47.40	8.50	16
	18	14.10	22.29	43.12	9-9.5	15-15.5
15	19	18.40	27.67	45 88	9	15

Figure 2 is a graphical representation of the dissolution curve obtained with Examples 16-19.

20

Examples 20-28

Slow release propranolol tablets are prepared according to the procedures set forth in Examples 1 and 25 2 which illustrate various aspects of the present invention, including the addition of additional polysaccharide gums to the xanthan/locust bean gum mixture, and variances in the ratio of xanthan gum to locust bean gum. In Examples 20-22, the relative 30 percentages of xanthan gum to locust bean gum are about 0/100, 25/75 and 75/25, respectively. In Examples 23

-32-

and 24, 50% of the hydrophilic matrix is propylene glycol alginate (PGA) and 50% is xanthan gum/locust bean gum in a 1:1 ratio. Examples 25 and 26 are similar to Example 23, except that the propylene glycol alginate is replaced with hydroxypropylmethyl cellulose 15M and 100M, respectively (both grades commercially available from Dow Chemical). Example 27 is also similar to Example 23, except that the propylene glycol alginate is replaced with sodium alginate. In Example 28, the excipient includes only xanthan gum. In each of Examples 20-28, the inert diluent is dextrose. To the excipient mixture, 20mg propranolol hydrochloride is added. The tablets produced in each of Examples 20-27 weigh 350mg.

15 In Comparative Example C, the excipient is 30% hydroxypropylmethyl cellulose and 70% dextrose by weight. The tablets of Comparative Example C also weighs 350mg and includes 20mg of propranolol hydrochloride. Table 5 sets forth the gums used in
20 Examples 20-28 and Comparative Example C.

The dissolution of the tablets of Examples 20-28 and Comparative Example C is then tested in distilled

-33-

water in an automated USP dissolution apparatus. The results are provided in Table 6.

TABLE 5% Gums in Hydrophilic Material

	<u>Example</u>	<u>Xanthan</u>	Locust	<u>PGA</u>	<u>HPMC</u>	Na
			<u>Gum</u>			<u>Alginate</u>
20		-	100	-	-	-
21		25	75	-	-	-
15 22		75	25	-	-	-
23		25	25	50%	-	-
24		25	25	50%	-	-
25		25	25	-	50%	-
26		25	25	-	50%	-
20 27		25	25	-	-	50%
28		100%	-	-	-	-
C		-	-	-	100%	-

25

-34-

TABLE 6

Dissolution of Propranolol Hydrochloride

(350mg tablets, 20mg drug)

Example	% Gums in Excipient	Ratio of Drug/Gums	2hr	4hr	8hr	T ₅₀	T ₉₀
20	30%	1:5	32.13	46.06	62.06	4.5-5	18+
21	40%	1:6.5	22.54	30.71	45.96	8.5-9	16-16.5
22	40%	1:6.5	12.9	22.75	50.05	8	12.5-13
23	30%	1:5	23.35	39.05	75.70	5-5.5	9.5-10
24	40%	1:6.5	20.12	32.79	64.17	6-6.5	11-11.5
25	30%	1:5	37.54	50.04	65.00	4	15.5-16
26	30%	1:5	32.71	41.79	54.88	6-6.5	18
27	30%	1:5	25.12	44.38	100	4-4.5	6.5-7
28	30%	1:5	17.38	31.00	59.88	6-6.5	11-11.5
C	30%	1:5	52.25	74.85	94.85	1.5-2	7

Figure 3 is a graphical representation of the dissolution curves provided by Example 18 (xanthan gum/locust bean gum in a 1:1 ratio), Example 20 (100% locust bean gum), and Example 28 (100% xanthan gum). From the graph, it may be seen that the T₅₀ for Example 28 was longer than that for Example 20. The T₉₀ for Example 28, however, was shorter than that for Example 20. This result may be due to the fact that xanthan gum wets quicker than locust bean gum (thereby providing a quicker forming gel) but does not have as good gel strength as locust bean gum. The combination of xanthan

-35-

gum/locust bean gum provides an excipient which both wets quickly and has a high gel strength. The T_{50} provided by Example 18 is longer than either Example 20 or 28. The T_{90} of Example 18 also reflects the improved gel strength obtained by the combination of the gums over xanthan gum alone.

Figure 4 is another graphical representation showing the dissolution curve of Example 18 as compared to Comparative Example C (gum is hydroxypropylmethyl cellulose). This graph shows the synergistic effect of the combination of xanthan gum/locust bean gum as compared to a prior art hydrophilic gel matrix forming agent. One possible explanation for this phenomenon is that hydroxypropylmethyl cellulose does not wet as quickly nor form a gel matrix which is as strong as the gums used in Example 18, and therefore does not provide a sufficient slow release profile.

Examples 29-31

Propranolol hydrochloride tablets are prepared according to the procedures set forth in Examples 1 and 2. The tablets of Examples 29-31 have a total weight of 350mg, of which 20mg is the drug. The excipient

-36-

comprises 40% gums (xanthan gum/locust bean gum in a 1:1 ratio) and 60% of an inert diluent (lactose). The drug/gums ratio is about 1:6.5.

In Example 29, the dissolution of the tablets was
5 measured in an aqueous solution having a pH of 6.8. In Example 30, the dissolution of the tablets was measured in distilled water (pH=7). In Example 31, the dissolution of the tablets was measured in an acidic solution having a pH of 2.

10 The tablets of Examples 29-31 are then tested to determine their dissolution rates in environments having varied pH's (distilled water, pH 2, pH 6.8). The results are shown in Figure 5 which is a graphical representation of the percentage of dissolved drug over
15 time.

As can be seen from Figure 5, the dissolution times of the tablets in pH 6.8 and pH 2 are fairly close, while the dissolution time in unbuffered distilled water does not provide a similar profile.
20 From the graphical representation, it may be concluded that the dissolution of the medicament (in this case propranolol) does not vary greatly in ionic solutions,

-37-

even when the pH varies greatly, due to the relative insensitivity to pH of the excipients of the present invention.

-38-

Examples 32-36

Slow release excipients are prepared according to procedures set forth in Example 1. The excipients of Examples 32-36 each include dextrose and xanthan gum/locust bean gum in a 1:1 ratio. The percentage of gums as compared to the total weight of the excipient in Examples 32-36 are 30%, 40%, 50%, 60% and 70%, respectively. The viscosities of the excipients are then determined at four different RPM's using a #2 spindle on a Brookfield viscometer. The results are shown in Figure 6. As can be seen from the graph, the viscosity increases as the percentage of gum included in the excipient increases.

The preceding theories are offered solely by way of explanation and it is not intended that the invention be limited to this theory.

The examples provided above are not meant to be exclusive. Many other variations of the present invention would be obvious to those skilled in the art, and are contemplated to be within the scope of the appended claims.

CLAIMS

1. A free-flowing, directly compressible slow release granulation for use as a pharmaceutical excipient, comprising

from about 20 to about 60 percent by weight of a hydrophilic material comprising a heteropolysaccharide and a polysaccharide material capable of cross-linking said heteropolysaccharide in the presence of aqueous solutions, and

from about 40 to about 80 percent by weight of an inert pharmaceutical filler.

2. The granulation of claim 1, wherein said heteropolysaccharide comprises from about 10 to about 90 percent by weight and said polysaccharide material comprises from about 90 to about 10 percent by weight, of said hydrophilic material.

3. The granulation of claim 2, wherein said heteropolysaccharide comprises xanthan gum or derivatives thereof.

-40-

4. The granulation of claim 3, wherein said polysaccharide material comprises a galactomannan.

5. The granulation of claim 4, wherein the ratio of said xanthan gum to said galactomannan is about 1:1.

6. The granulation of claim 5, wherein said galactomannan comprises locust bean gum.

7. The granulation of claim 6, wherein said inert pharmaceutical filler comprises a monosaccharide, a disaccharide, a polyhydric alcohol, or mixtures thereof.

8. The granulation of claim 7, wherein said inert pharmaceutical filler comprises lactose, dextrose, sucrose, fructose, microcrystalline cellulose, xylitol, sorbitol or mixtures thereof.

9. The granulation of claim 1 to which an effective amount of a therapeutically active ingredient is added.

-41-

10. The granulation of claim 1, wherein an effective amount of a therapeutically active ingredient is added and the resultant mixture is compressed to form solid tablets.

11. The granulation of claim 10, wherein at least 3.5 hours are required to release 50 percent of said therapeutically active ingredient.

12. The granulation of claim 11, wherein the average particle size of said granules is from about 185 to about 250 microns.

13. The granulation according to claim 4, wherein said hydrophilic matrix further comprises a second polysaccharide material comprising tragacanth, accacia, karaya, alginates, agar, pectin, guar, hydroxypropyl guar, carrageenan, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methylcellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, mixtures of any of the foregoing, or the like.

14. The granulation according to claim 1, wherein an effective amount of a therapeutically active ingredient is added and the resulting mixture is encapsulated.

15. The granulation according to claim 1, wherein an effective amount of a therapeutically active ingredient is added and the resulting mixture provides a zero order controlled release when provided as a solid dosage form.

16. A free-flowing slow release granulation for use as a directly compressible pharmaceutical excipient, comprising a heteropolysaccharide and an effective amount of a cross-linking agent capable of cross-linking said heteropolysaccharide in aqueous solutions.

17. The granulation according to claim 16, wherein said heteropolysaccharide comprises xanthan gum and said cross-linking agent comprises locust bean gum in a ratio of about 1:1.

-43-

18. The granulation according to claim 16, further comprising an inert pharmaceutical filler.

19. The granulation according to claim 18, wherein an effective amount of a therapeutically active ingredient is added and the resulting mixture provides a zero order controlled release when provided as a solid dosage form.

20. A slow release tablet for oral administration comprising a directly compressible free-flowing granulation comprising

(I) from about 20 to about 60 percent by weight of a hydrophilic material comprising

(a) a heteropolysaccharide; or

(b) a heteropolysaccharide and a cross-linking agent capable of cross-linking said heteropolysaccharide; or

(c) a mixture of (a), (b) and a polysaccharide gum; and

(II) up to about 80 percent of an inert pharmaceutical filler; and

-44-

(III) an effective amount of a therapeutically active ingredient.

21. The tablet according to claim 20, wherein said heteropolysaccharide comprises xanthan gum, said cross-linking agent comprises a galactomannan, and the ratio of xanthan gum to locust bean gum is about 1:1.

22. The tablet according to claim 20, wherein said polysaccharide gum comprises tragacanth, accacia, karaya, alginates, agar, pectin, guar, hydroxypropyl guar, carrageenan, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methylcellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, mixtures of any of the foregoing, or the like.

23. The tablet according to claim 30, wherein the ratio of said active ingredient to said hydrophilic material is from about 1:3 to about 1:7.

24. A method for providing a universal tableting

-45-

granulated excipient which is free-flowing and directly compressible for a controlled release of a relatively soluble or insoluble therapeutically active medicament comprising

determining the solubility of a therapeutically active medicament which is to be tableted;

mixing an effective amount of said therapeutically active medicament with a premanufactured granulated slow release excipient comprising from about 30 to about 50 percent by weight of a hydrophilic material comprising a heteropolysaccharide and a polysaccharide capable of cross-linking said heteropolysaccharide in the presence of gastric fluid and from about 50 to about 70 percent by weight of an inert pharmaceutical filler;

providing a final mixed product having a ratio of said therapeutically active medicament to said hydrophilic material of about 1:3-7 and a sufficient amount of said hydrophilic material such that a gel matrix is created when said tablet is exposed to gastric fluid and such that at least 3.5 hours are required for 50 percent of said therapeutically active medicament to

-46-

be released following exposure to gastric fluid, and thereafter directly compressing the resulting blend to form a tablet.

25. The method according to claim 24, wherein said heteropolysaccharide is xanthan gum and said polysaccharide is locust bean gum in a 1:1 ratio.




FIG. 1




FIG. 2 SUBSTITUTE SHEET

2/3




FIG. 3




FIG. 4

SUBSTITUTE SHEET

3/3




FIG. 5




FIG. 6

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/03968

I. CLASSIFICATION F SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (4): A61K 9/26		
U.S. CL: 424/469		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System:	Classification Symbols	
U.S.	424/78, 80, 464, 468, 469, 470, 488, 499	
Documentation Searched other than Minimum Documentation to the extent that such documents are included in the fields searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	US, A, 4,199,560 (GYARMATI) 22 APRIL 1980 See entire document	1-25
Y	US, A, 4,698,264 (STEINKE) 06 OCTOBER 1987 See entire document	1-25
P,Y	US, A, 4,792,452 (HOWARD) 20 DECEMBER 1988 See entire document	1-25
P,Y	US, A, 4,828,836 (ELGER) 09 MAY 1989 See entire document	1-25
P,Y	US, A, 4,855,143 (LOWEY) 08 AUGUST 1989 See entire document	1-25
<p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 27 NOVEMBER 1989		Date of Mailing of this International Search Report 08 JAN 1990
International Searching Authority ISA/US		Signature of Authorized Officer T.K. PAGE - TK/Agi